News
Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...
Stocktwits on MSN2h
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EUVertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...
Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare ...
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.
Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback